Hemodialysis requires repeated access to the blood. Failure to maintain adequate access to the vasculature is a major cause of medical complications and, potentially, death for these patients. A new study in The American Journal of Pathology provides information about the mechanisms underlying failure of the most common type of hemodialysis vascular access, the arteriovenous fistula. Despite being the preferred approach, there is currently limited understanding of the mechanisms involved in fistula maturation failure.
Researchers at the Johns Hopkins University School of Medicine and the Mayo Clinic have compiled peer-reviewed evidence and crafted a guideline designed to help physicians and medical centers stop the use of a widely ordered blood test that adds no value in evaluating patients with suspected heart attack.
Researchers in the Netherlands have designed a different approach to the liquid biopsy. Rather than looking for evidence of cancer DNA or other biomarkers in the blood, their test (called thromboSeq) could diagnose non-small cell lung cancer with close to 90 percent accuracy by detecting tumor RNA absorbed by circulating platelets, also known as thrombocytes. Non-small cell lung cancers make up the majority of lung cancer cases. The research appears Aug. 14 in Cancer Cell.
University of British Columbia investigators have found that measuring changes in red blood cell deformability is a robust, sensitive method for inferring heme-induced oxidative stress. Using a simple UBC-developed device that measures RBC deformability, malaria progression may be assessed in a matter of minutes.
In contrast to what has been previously believed, development of blood stem cells to mast cells, a type of specialised immune cell, does not depend on a growth factor called stem cell factor. This has been demonstrated in a new collaborative study by researchers at Karolinska Institutet and Uppsala University, and published in the scientific journal Blood. The results could pave the way for new treatments for certain types of blood diseases.
Researchers at St. Michael's Hospital have identified how natural killer cells in the mouse placenta can cause a fetus to fail to grow in the womb or cause miscarriages.
Some patients may have a genetic risk of developing a serious side effect to a type of medication commonly used to treat high blood pressure, research by clinicians and scientists at the University of Nottingham has found.
Lifestyle intervention is the best approach in preventing Type 2 diabetes. However, most patients don't follow through in having a balanced diet and exercise. Prescribing metformin can save $820 million annually in healthcare costs and reduce the number of Type 2 diabetes patients by 20%.
St. Jude Children's Research Hospital scientists have found that cells of a deadly acute myeloid leukemia can be killed by blocking production of a molecular 'battery.'
A new class of anti-cancer agents targeting cancer cells' 'Achilles' heel' could help to supercharge breast cancer treatment, improving outcomes for the most aggressive types of breast cancer. Combining anti-cancer compound S63845 with currently used cancer drugs was more effective in killing triple negative breast cancers and HER2-positive breast cancers. This is the first time the S63845 compound has been shown to be effective in breast cancer, suggesting it should be investigated in clinical trials.